Hannah Blau, M.B.B.S, Joins AIT's Scientific Advisory Board

Dec 16, 2013, 07:02 ET from Advanced Inhalation Therapies (AIT)

REHOVOT, Israel, December 16, 2013 /PRNewswire/ --


Advanced Inhalation Therapies (AIT), a leader in the development of innovative therapeutics for the treatment of infectious respiratory diseases, announced today the appointment of Hannah Blau, M.B.B.S,to its scientific advisory board.

Prof. Hannah Blau holds the position of Director, Pulmonary institute & Chair of the Graub Cystic Fibrosis Center, Schneider Children's Medical Center of Israel, and is an Associate Professor at Tel Aviv University.

"I am very pleased to welcome Dr. Hannah Blau to AIT's SAB.  Her tremendous expertise and researches in the field of cystic fibrosis will greatly contribute to AIT in its advanced studies. In the following months we will start a Phase II multi center study for subjects with CF in our CF program and having Dr. Hannah Blau on board is a great honor for us " says David Greenberg M.D., Chief Medical Officer at AIT and a  Professor of Pediatrics and Infectious Diseases at the Soroka Medical Center in Beer Sheva, Israel.

Cystic fibrosis is an inherited chronic disease that affects the lungs and digestive system of about 30,000 children and adults in the United States (70,000 worldwide). A defective gene and its protein product cause the body to produce unusually thick, sticky mucus that:

  • Clogs the lungs and leads to life-threatening lung infections
  • Obstructs the pancreas
  • Stops natural enzymes from helping the body break down and absorb food.

"I am honored to join AIT's scientific advisory board, said Dr. Blau." CF is a life threating disease that affects so many children and adults around the world. I believe there is a great potential using formulation of Nitric Oxide to help and bring a new solution for the airway infections, often with multi-resistant bacteria and fungi that afflict CF patients. I am looking forward to working alongside AIT's experienced management team as they continue to advance the Company's pipeline and forge new strategic collaborations within the industry."

AIT focuses on the development of unique nitric oxide formulations for the treatment of respiratory infectious diseases, including human respiratory syncytial virus (RSV), bronchiolitis, cystic fibrosis, pneumonia and asthma. The company is currently conducting multi-center Phase II trials in children and adults with CF as well as a Phase II for human respiratory syncytial virus (RSV) & bronchiolitis in infants. Mid-study results in bronchiolitis (children Pneumonia) demonstrated the safety of AIT's nitric oxide formulation in children.

About AIT

AIT (http://www.ait-pharm.com) is an Israeli biomed company focused on the development and commercialization of formulations from nitric oxide for the treatment of infectious diseases. The company was founded in 2011 by Mor Research Applications, a subsidiary of Clalit Health Services, Israel's largest health management organization.

The company is conducting Phase II trials on bronchiolitis after successful completion of Phase I trials. AIT develops products for the treatment of bronchiolitis, pneumonia, cystic fibrosis and asthma.

About Clalit Health Services

Schneider Children's Medical Center is a member of Clalit Health Services, the largest HMO in Israel, and one of the most progressive public health associations in the world. Through its 14 hospitals and more than 1,400 primary and specialized clinics, Clalit provides comprehensive health insurance and highly advanced medical care to the majority of Israel's population. It is also the only health fund with a countrywide network of 425 state-of-the-art pharmacies, 70 dental clinics, 80 clinical laboratories, 35 separate radiology facilities, as well as computerized diagnostic equipment at a number of central laboratories.

Clalit has 4 million insured members in Israel (>52% market share).

Clalit is the only health organization that has an extensive network of hospitals throughout the country. Clalit maintains a total of 14 general and special care hospitals which are all university affiliate

In the long-term interest of the entire population, Clalit conducts clinical, biomedical, and social science research in its own facilities, or in cooperation with Israel's universities and scientific institutions.

Contact information
Racheli Vizman, COO, AIT
2 Derech Meir Weisgal
Rehovot 9632605, Israel
E-mail: racheli@ait-pharm.com
Direct: +972-8-684-3313
Mobile: +972-52-565-9922

SOURCE Advanced Inhalation Therapies (AIT)